Brief: Alto Neuroscience Announces Initiation Of Phase 2 Study Of ALTO-203 In Patients With Major Depressive Disorder
03/04/2024 14:21
April 3 (Reuters) - Alto Neuroscience Inc ANRO.N :
* ALTO NEUROSCIENCE ANNOUNCES INITIATION OF PHASE 2 STUDY OF
ALTO-203 IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Source text for Eikon: ID:nBw7jNRPga
Further company coverage: ANRO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alto Neuroscience
See all newsBrief: Alto Neuroscience Promotes Nick Smith To President And Chief Financial Officer
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: Alto Neuroscience - Proposed Resale Of Up To 6 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Brief: Alto Neuroscience Reports Topline Data From Phase 2 Proof-Of-Concept Study Of Alto-101 And Highlights Pipeline Advancements